drugset / Trial / NCT00722501
Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of ERB-257 in healthy subjects
Timeline
- Start
- 2008-08
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ERB-257 | Unknown | 1 mg | Intravenous |
| Comparator | ERB-257 | Unknown | 4 mg | Intravenous |
| Comparator | ERB-257 | Unknown | 15 mg | Intravenous |
| Comparator | ERB-257 | Unknown | 45 mg | Intravenous |
| Comparator | ERB-257 | Unknown | 90 mg | Intravenous |
| Comparator | ERB-257 | Unknown | 180 mg | Intravenous |
| Comparator | ERB-257 | Unknown | 300 mg | Intravenous |
Indications
No indication recorded.